Nicholas Lee Gurreri
Plus aucun poste en cours
Profil
Nicholas Lee Gurreri worked as a Senior Director at Pfizer Inc. from 2003 to 2007 and as a Director at Pharmacia Corp.
from 2000 to 2003.
He also held positions as a Principal at Bristol Myers Squibb Co. and BMS A, and as a Senior Vice President at Insmed, Inc. from 2010 to 2011.
Gurreri's last known position was as SVP of Commercial Operations and Business Development at Transave, Inc. Gurreri holds a graduate degree from Carnegie Mellon University and an undergraduate degree from the University of Delaware.
Anciens postes connus de Nicholas Lee Gurreri
| Sociétés | Poste | Fin |
|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | 01/06/2007 |
Pharmacia Corp.
 Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ. | Corporate Officer/Principal | 01/04/2003 |
| INSMED INCORPORATED | Directeur des opérations | - |
BMS A/S
 BMS A/S Finance/Rental/LeasingFinance BMS A/S is a private company based in Aalborg, Denmark. The company's headquarters is located at Sofiendalsvej 94a, 1st floor, Denmark-9200 Aalborg SV. BMS provides login services and can be contacted via phone at +45 7242 0200 or email at mail@bms.dk. The Danish company can also be followed on their website at bms. | Corporate Officer/Principal | - |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Formation de Nicholas Lee Gurreri
| Carnegie Mellon University | Graduate Degree |
| University of Delaware | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| PFIZER, INC. | Health Technology |
| INSMED INCORPORATED | Health Technology |
| Entreprise privées | 3 |
|---|---|
BMS A/S
BMS A/S Finance/Rental/LeasingFinance BMS A/S is a private company based in Aalborg, Denmark. The company's headquarters is located at Sofiendalsvej 94a, 1st floor, Denmark-9200 Aalborg SV. BMS provides login services and can be contacted via phone at +45 7242 0200 or email at mail@bms.dk. The Danish company can also be followed on their website at bms. | Finance |
Pharmacia Corp.
Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ. | Health Technology |
Transave, Inc.
 Transave, Inc. Pharmaceuticals: MajorHealth Technology Transave, Inc. is a biopharmaceutical company focused on developing innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. They are committed to significantly improving the quality of life and healthcare of patients suffering from these life-threatening diseases. Its operating principles are centered on teamwork, openness, mutual respect, diversity of opinion, trust, accountability and innovative science. They are developing products based on Transave's proprietary liposomal technology designed specifically for lung delivery. Its focus is on reformulating off-patent, established drugs into unique liposomal technology - based inhaled pharmaceuticals for the localized, site-specific treatment of serious lung diseases. Transave's proprietary liposomal technology allows for the sustained release of a drug in the lung's microenvironment. By remaining in the lungs for a prolonged period and potentially minimizing systemic exposure, Transave's liposomal technology offers the potential for changing the product profile, improving delivery of the compound to the lung and enhancing the therapeutic index of established pharmaceuticals. | Health Technology |
